Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telazorlimab (ISB 830) in Moderate to Severe Atopic Dermatitis
NCT03568162Phase 2Completed
- Sponsor
- Ichnos Sciences Inc.
- Start
- May 2018
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of telazorlimab in atopic dermatitis (AD), sponsored by Ichnos Sciences Inc.. Started May 2018; status: completed.
02
Drugs
telazorlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03568162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568162.